2023
Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Roseberry K, Le-Niculescu H, Levey D, Bhagar R, Soe K, Rogers J, Palkowitz S, Pina N, Anastasiadis W, Gill S, Kurian S, Shekhar A, Niculescu A. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2023, 28: 2894-2912. PMID: 36878964, PMCID: PMC10615756, DOI: 10.1038/s41380-023-01998-0.Peer-Reviewed Original ResearchConceptsIndependent cohortCandidate biomarkersPsychiatric subjectsPersonalized approachConvergent functional genomics approachAnxiety disordersBest overall evidenceAdverse life eventsClinical worseningGene expression signaturesBlood biomarkersAnxiety medicationClinical utilityPsychiatric disordersHigh anxiety stateSevere anxietyUntreated anxietyDecrease qualityIndividual biomarkersAddiction potentialBiomarkersTop biomarkersAnxiety statesRisk predictionExpression signatures
2021
Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, Williams A, Bhairo S, Voegtline T, Davis H, Shekhar A, Kurian SM, Niculescu AB. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2021, 26: 2776-2804. PMID: 33828235, PMCID: PMC8505261, DOI: 10.1038/s41380-021-01061-w.Peer-Reviewed Original ResearchMeSH KeywordsDrug RepositioningHumansMood DisordersPharmacogeneticsPrecision MedicineReproducibility of ResultsRisk AssessmentConceptsBlood gene expression biomarkersTop candidate biomarkersMood disordersIndependent cohortStrongest overall evidenceBlood testsTop biomarkersGene expression biomarkersCandidate biomarkersConvergent functional genomics approachMood statesPotential new antidepressantsPsychiatric disorder patientsOverall evidenceVisual analog scaleSimple visual analog scaleMatching of patientsPanel of biomarkersPrecision medicineMonitoring of responseBipolar mood disorderExpression biomarkersCell differentiation functionsObjective assessmentSevere mania
2019
Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs
Le-Niculescu H, Roseberry K, Levey D, Rogers J, Kosary K, Prabha S, Jones T, Judd S, McCormick M, Wessel A, Williams A, Phalen P, Mamdani F, Sequeira A, Kurian S, Niculescu A. Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs. Molecular Psychiatry 2019, 25: 918-938. PMID: 30862937, PMCID: PMC7192849, DOI: 10.1038/s41380-019-0370-z.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultBeta 2-MicroglobulinBiomarkersDEAD-box RNA HelicasesFemaleGene ExpressionHumansMaleMental DisordersMiddle AgedMolecular Targeted TherapyNogo ProteinsPrecision MedicinePredictive Value of TestsProto-Oncogene ProteinsReceptors, ImmunologicStress, PsychologicalTacrolimus Binding ProteinsTelomere HomeostasisConceptsPredictive biomarkersGene expression biomarkersTelomere lengthBlood gene expression biomarkersPossible new drug candidateStress disorderPsychological stressFuture psychiatric hospitalizationsVisual analog scaleHigh-risk groupSimple visual analog scaleDrug repurposing analysisExpression biomarkersGene expression signaturesAnalog scaleAdverse outcomesCalcium folinateCohort designHormonal changesPsychiatric hospitalizationDecreased qualityBiomarker findingsPsychiatric disordersPsychiatric patientsPatient stratificationTowards precision medicine for pain: diagnostic biomarkers and repurposed drugs
Niculescu A, Le-Niculescu H, Levey D, Roseberry K, Soe K, Rogers J, Khan F, Jones T, Judd S, McCormick M, Wessel A, Williams A, Kurian S, White F. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Molecular Psychiatry 2019, 24: 501-522. PMID: 30755720, PMCID: PMC6477790, DOI: 10.1038/s41380-018-0345-5.Peer-Reviewed Original ResearchConceptsBlood gene expression biomarkersPossible new drug candidateFuture emergency department (ED) visitsEmergency department visitsHigh-risk groupDrug repurposing analysisCurrent opioid epidemicPerception of painSubjects longitudinal designGene expression signaturesPain statesDepartment visitsPain disordersTreatment dilemmaBlood biomarkersSC-560Opioid epidemicCohort designRisk groupsIndependent cohortPainGene expression biomarkersPsychiatric patientsDiagnostic biomarkersIndividual biomarkers
2017
Precision medicine for suicidality: from universality to subtypes and personalization
Niculescu A, Le-Niculescu H, Levey D, Phalen P, Dainton H, Roseberry K, Niculescu E, Niezer J, Williams A, Graham D, Jones T, Venugopal V, Ballew A, Yard M, Gelbart T, Kurian S, Shekhar A, Schork N, Sandusky G, Salomon D. Precision medicine for suicidality: from universality to subtypes and personalization. Molecular Psychiatry 2017, 22: 1250-1273. PMID: 28809398, PMCID: PMC5582166, DOI: 10.1038/mp.2017.128.Peer-Reviewed Original ResearchConceptsSuicidal ideationIndependent cohortPersonalized approachFuture hospitalizationPsychiatric diagnosisCandidate biomarkersUniversal biomarkerBlood gene expression biomarkersBiology of suicideTop biomarkersNovel predictive biomarkerHigh-risk groupNon-psychiatric disordersDrug repurposing analysisPublic health problemMonitoring of responseNovel potential therapeuticsHigher suicidal ideationPredictive biomarkersClinical trialsComprehensive stepwise approachRisk groupsLarge cohortMood disordersPreventive therapeutics